Dry Age-Related Macular Degeneration – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of dry age-related macular degeneration comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of dry age-related macular degeneration for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s diabetic macular edema forecast will answer the following questions:
- Of all people with dry age-related macular degeneration, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with dry age-related macular degeneration, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dry age-related macular degeneration over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts nine dry age-related macular degeneration patient populations, as follows:
- Total prevalent cases of dry AMD
- Total prevalent cases of dry AMD without co-existing wet AMD
- Total prevalent cases of mixed AMD
- Total prevalent cases of fovea-involved dry AMD
- Total prevalent cases of non-fovea-involved dry AMD
- Diagnosed prevalent cases of dry AMD
- Undiagnosed prevalent cases of dry AMD
- Diagnosed drug-treated prevalent cases of dry AMD
- Diagnosed non-drug-treated prevalent cases of dry AMD
Note: Coverage may vary by country.
Table of contents
- Dry Age-Related Macular Degeneration - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of dry AMD)
- Total prevalent cases of dry AMD
- Total prevalent cases of dry AMD without co-existing wet AMD
- Total prevalent cases of mixed AMD
- Total prevalent cases of fovea and non-fovea-involved dry AMD
- Diagnosed and drug-treated prevalent cases of dry AMD
- Risk / protective factors applied to disease forecast models
- Reference Materials
